Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab

Clinical Pharmacokinetics
Kazunao Kondo, Kazuo Umemura

Abstract

Tirofiban is a nonpeptide tyrosine derivative that antagonises platelet glycoprotein IIb/IIIa (GP IIb/IIIa) receptors. It is one of three GP IIb/IIIa antagonists approved by the US Food and Drug Administration for the treatment of patients with acute coronary syndromes. The clinical effect of tirofiban has been shown in large studies such as PRISM (Platelet Receptor Inhibition for Ischemic Syndrome Management), PRISM-PLUS (PRISM - Patients Limited by Unstable Signs and Symptoms) and RESTORE (Randomised Efficacy Study of Tirofiban for Outcomes and Restenosis). Tirofiban is administered as an intravenous infusion. Volume of distribution ranges from 21 to 87 L, and binding to human plasma proteins is modest at 64%. Metabolism in humans is negligible, and most drug is excreted renally with systemic clearance ranging from 4.8 to 25.8 L/h. Renal function may influence the excretion of tirofiban, but concurrent disease or other drugs generally used in patients with ischaemia seem not to do so. This review updates what is known about the pharmacokinetics of tirofiban in humans, especially in comparison with the monoclonal antibody against the IIb/IIIa receptor, abciximab.

References

Jun 23, 2001·The New England Journal of Medicine·E J TopolUNKNOWN TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial

❮ Previous
Next ❯

Citations

Dec 6, 2006·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·S M SaidR Prondzinsky
Oct 22, 2013·Current Atherosclerosis Reports·Kiran KalraPaul A Gurbel
Oct 13, 2010·Pharmacogenetics and Genomics·Katrin SangkuhlRuss B Altman
Oct 3, 2008·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Burcak Kilickiran AvciOsman Ozcebe
May 1, 2006·Future Cardiology·Udaya S TantryPaul A Gurbel
Apr 28, 2005·Expert Review of Cardiovascular Therapy·Alberto MenozziDiego Ardissino
Dec 24, 2005·Expert Opinion on Pharmacotherapy·Simone C BukowMichael G Hennerici
Apr 13, 2007·Expert Opinion on Drug Metabolism & Toxicology·Debabrata Mukherjee, Marco Roffi
Jun 19, 2003·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Virginia A BowbrickGerard Stansby
Jul 10, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Nandhakishore RajagopalanR Manjunatha Kini
Oct 30, 2018·Journal of Cerebrovascular and Endovascular Neurosurgery·Sang Hyub LeeChul Hee Lee
Jul 15, 2021·Clinical and Molecular Allergy : CMA·Seo-Hee KimYoo Seob Shin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.

© 2022 Meta ULC. All rights reserved